Victory Capital Management Inc Arbutus Biopharma Corp Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$1.9 - $2.27 $1,548 - $1,850	815 Added 6.27%	13,810 $28,000
Q2 2023 Jul 27, 2023	SELL	$2.24 - $3.06 $676 - $924	-302 Reduced 2.27%	12,995 $29,000
Q1 2023 May 02, 2023	BUY	$2.23 - $3.1 $29,652 - $41,220	13,297 New	13,297 $40,000
Q4 2018 Feb 05, 2019	SELL	$3.5 - $9.66 $528,710 - $1.46 Million	-151,060 Closed	0 $0
Q3 2018 Nov 01, 2018	SELL	$7.85 - $12.35 $60,131 - $94,601	-7,660 Reduced 4.83%	151,060 $1.43 Million

Q2 2018 Aug 02, 2018	SELL	$5.0 - $7.35 $42,150 - $61,960	-8,430 Reduced 5.04%	158,720 $1.16 Million
Q1 2018 May 04, 2018	BUY	$4.4 - $6.05 $72,292 - $99,401	16,430 Added 10.9%	167,150 $836,000
Q4 2017 Feb 01, 2018	BUY	$4.45 - $7.7 $95,497 - $165,242	21,460 Added 16.6%	150,720 $761,000
Q3 2017 Oct 27, 2017	SELL	$3.4 - $7.0 $12,070 - $24,850	-3,550 Reduced 2.67%	129,260 $801,000
Q2 2017 Aug 07, 2017	BUY	N/A	132,810	132,810 $478,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.